Filing Details

Accession Number:
0000899243-18-022840
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-08-20 20:25:21
Reporting Period:
2018-08-16
Accepted Time:
2018-08-20 20:25:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1629137 Global Blood Therapeutics Inc. GBT Pharmaceutical Preparations (2834) 274825712
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1730866 Ann Lesley Calhoun C/O Global Blood Therapeutics, Inc.
171 Oyster Point Blvd., Suite 300
South San Francisco CA 94080
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-07-31 204 $35.53 1,342 No 4 A Direct
Common Stock Disposition 2018-08-16 204 $49.97 1,138 No 4 S Direct
Common Stock Acquisiton 2018-08-16 500 $22.00 1,638 No 4 M Direct
Common Stock Acquisiton 2018-08-16 1,000 $22.00 2,638 No 4 M Direct
Common Stock Disposition 2018-08-16 1,500 $50.01 1,138 No 4 S Direct
Common Stock Disposition 2018-08-17 300 $49.19 838 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-08-16 500 $0.00 500 $22.00
Common Stock Stock Option (Right to Buy) Disposition 2018-08-16 1,000 $0.00 1,000 $22.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
26,205 No 4 M Direct
25,205 No 4 M Direct
Footnotes
  1. Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan.
  2. Represents the weighted average sale price of the shares sold ranging from $50.0000 to $50.0304 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  3. The Stock Option becomes exercisable with respect to 1/4th of the underlying shares on August 15, 2017 and with respect to an additional 1/12th of the underlying shares each quarter thereafter until fully vested on August 15, 2020, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.